

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	10/593,710 September 21, 2006 Louise D. McCullough, et al 1632 Not Yet Assigned P71492US/37049.00070
Sheet	1	of	3		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)				
		WO 2001/023399	04-05-2001	Pfizer Products, Inc et al		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Include if reference considered, whether or not citation is in conformance with MPPEP 609. Draw line through citation if not in conformance and not considered. Initial copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 9). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>		
		Application Number	10/593,710	
		Filing Date	September 21, 2006	
		First Named Inventor	Louise D. McCullough, et al	
		Art Unit	1632	
Examiner Name	Not Yet Assigned			
Sheet	2	<<3>>	Attorney Docket Number	P71492US/37049.00070

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†2
		KIM Y. K. <i>et al.</i> , "Expression of FAS with Hypothalamic Neurons: a Model for Decreased Food Intake after C75 treatment," <i>Endocrinol Metab.</i> 283, E867-E879 (2002).	
		LEON J. <i>et al.</i> , "Modulation of Rat Striatal Glutamatergic Response in Search for New Neuroprotective Agents: Evaluation of Melatonin and Some Kynurenine Derivatives," <i>Brain Research Bulletin</i> , 45, 525-530 (2003).	
		SHENG R. <i>et al.</i> , "EDT, a Tetrahydroacridine Derivative Inhibits Cerebral Ischemia and Protects Rat Cortical Neurons Against Glutamate-Induced Cytotoxicity," <i>Acta Pharmacol Sin</i> 24(5) 390-393 (May 2003).	
		CARLING, D., "The AMP-Activated Protein Kinase Cascade – a Unifying System for Energy Control," <i>Trends in Biochemical Sciences</i> , 29(1) 18- 24 (January 2004).	
		WITTESS, L., <i>et al.</i> , "Insulin Activation of Acetyl-CoA Carboxylase Accompanied by Inhibition of the 5'-AMP-Activated Protein Kinase," <i>The J. of Biol. Chem.</i> , 267(5), 2864-2867 (February 1992).	
		ZHIHONG, H., <i>et al.</i> , "Effects of Cerebral Ischemia in Mice Deficient in Neuronal Nitric Oxide Synthase," <i>Science</i> 265, 1883-1885 (September 1994).	
		ELIASSON, M. <i>et al.</i> , "Poly(ADP-ribose) Polymerase Gene Disruption Renders Mice Resistant to Cerebral Ischemia," <i>Nature Medicine</i> 3(10) 1089-1095 (October 1997).	
		HAWLEY, S. <i>et al.</i> , "Characterization of the AMP-activated Protein Kinase from Rat Liver and Identification of Threonine 172 as the Major Site at Which it Phosphorylates AMP-activated Protein Kinase," <i>J. of Biol. Chem.</i> 271(44), 27879-27887 (November 1996).	
		HARDIE, D. G. <i>et al.</i> , "AMP-Activated Protein Kinase: an Ultrasensitive system for Monitoring Cellular Energy Charge," <i>Biochem J.</i> 338, 717-722 (1999).	
		MCCULLOUGH, L. <i>et al.</i> , "Neuroprotective Function of the PGE <sub>2</sub> EP2 Receptor in Cerebral Ischemia," <i>J. of Neuroscience</i> 24(1) 257-268 (January 2004).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/593,710		
		Filing Date	September 21, 2006		
		First Named Inventor	Louise D. McCullough, et al		
		Art Unit	1632		
		Examiner Name	Not Yet Assigned		
Sheet	3	of	<<3>>	Attorney Docket Number	P71492US/37049.00070

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MCCULLOUGH, L. <i>et al.</i> "Postischemic Estrogen Reduces Hypoperfusion and Secondary Ischemia After Experimental Stroke" <i>Stroke</i> 32, 796-802 (2001).	
		ZHOU, <i>et al.</i> , "Role of AMP-activated Protein Kinase in Mechanism of Metformin Action," <i>J. of Clinical Investigation</i> 108(8) 1167-1174 (October 2001).	
		CORTON, <i>et al.</i> , "5-A Minoimidazole-4-Carboxamide Ribonucleoside A Specific Method for Activating AMP-Activated Protein Kinase in Intact Cells?" <i>Eur J. Biochem.</i> 229, 558-565 (1995).	
		ALMEIDA, A. <i>et al.</i> "Nitric Oxide Switches On Glycolysis Through The AMP Protein Kinase And 6-Phosphofructo-2-Kinase Pathway," <i>Nature Cell Bio.</i> 6, 45-51 (January 2004).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.